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Xinping Xi2* , Mei Zhou2 and Tianbao Chen2
1 Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese
Medicine, Nanjing, China, 2 Natural Drug Discovery Group, School of Pharmacy, Faculty of Medicine, Health and Life
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Public health is confronting the threat caused by antibiotic resistance and this means
new antibacterial strategies must be developed urgently. Antimicrobial peptides (AMPs)
have been considered as promising therapeutic candidates against infection in the post-
antibiotic era. In this paper, we dismissed the significance of “Rana box” in the natural
nigrocin-HL identified from skin secretion of Hylarana latouchii by comparing its activity
with nigrocin-HLD without the motif. By substituting the “Rana box” sequence with
an amidated phenylalanine residue, the natural peptide was modified into a shorter
AMP nigrocin-HLM. Activities and toxicities of these two peptides in vitro and in vivo
were compared. As a result, nigrocin-HLM not only displayed significantly increased
potency against several representative microbes, but also high activity against the
antibiotic-resistant methicillin-resistant S. aureus (MRSA, NCTC 12493 and ATCC43300
and several clinical isolates) as evidenced by markedly reduced minimal inhibitory
concentration (MIC), minimal bactericidal concentration (MBC), and minimum biofilm
eradication concentration (MBEC). More strikingly, nigrocin-HLM exhibited prominent
inhibition against MRSA infection in a pneumonia mice model. In addition, the
substitution attenuated the toxicity of nigrocin-HLM as evidenced by precipitously
decreased hemolytic and cytotoxic activities in vitro, and acute toxicity to mice in vivo.
Taken these results into consideration, nigrocin-HLM should be a promising therapeutic
candidate for anti-infection. And in addition to dismiss an indispensable role of “Rana
box” in maintaining antimicrobial activity of nigrocin-HL, our data provided an inspired
strategy for peptide optimization.
Keywords: nigrocin, Rana box, modification, MRSA, antibiotic resistance, pneumonia
INTRODUCTION
Antibiotic resistance has disseminated rapidly because of multifactorial reasons including
indiscriminate use and some complex ancient antibiotic-resistance mechanisms of
bacteria (Brown and Wright, 2016; Dickey et al., 2017). To illustrate, as a developed
strain of Staphylococcus aureus (S. aureus) through horizontal gene transfer and natural
selection, MRSA could induce numerous infections of skin, bone, joint, soft-tissue,
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respiratory system and central nervous system (Liu et al., 2011;
Gurusamy et al., 2013). To date, vancomycin has been considered
as the best therapeutic agent to deal with infections caused by
MRSA, but its disadvantages like extravascular diffusion and
relatively slow action may lead to its decreased efficacy in vivo
(Michel and Gutmann, 1997). Although the in vitro potency
of combination treatment of vancomycin with some other
antibiotics has been demonstrated, their mechanisms targeting
specific phase of cell growth and proliferation may still permit
MRSA to develop resistance to them. In consequence, it facilitates
clinicians and researchers to develop new therapeutic approaches
with broad-spectrum activity and selectivity to address the crisis.
Compared with conventional antibiotics, AMPs are reported
to possess unique membrane-disrupting antimicrobial mode
of actions represented by some structurally defined models
including barrel-stave, toroidal and detergent-like carpet models,
etc. (Mahlapuu et al., 2016). Furthermore, a majority of
intracellular activity possessed by AMPs have been reported,
which include inhibition of DNA, RNA and protein synthesis,
protease, cell wall biosynthesis, cell metabolism and so on.
Hence, it is logical that antimicrobial activity of an AMP
could be a mixture of several modes of action happening
concurrently, which makes pathogens virtually impossible to
develop resistance to them in sharp contrast with traditional
antibiotics (Fjell et al., 2011; Scocchi et al., 2016; Grassi
et al., 2017; Le et al., 2017). Some motifs in AMPs have
been considered as pivotal for them to possess antimicrobial
activity and structural stability while some other studies refuted
the indispensable roles of these highly conserved sequences.
To illustrate, study on brevinin 1E amide suggested that the
disulphide bridge was pivotal for the α-helical structure but not
significant for its antimicrobial potency, as activity was unaffected
even when cysteine residues are substituted by serine (Kwon
et al., 1998). In contrast, the elimination of the heptapeptide
motif in B1CTcu5, an AMP isolated from Clinotarsus curtipes,
prominently reduced antibiotic and hemolytic activity of it
(Abraham et al., 2015). Nigrocin is a representative anuran AMP
family, and after sequence alignment between nigrocin-HL and
other members of nigrocin family reported previously, a highly
conserved heptapeptide motif “CGLXGLC” named “Rana box”
at C-terminus was confirmed in the nigrocin family (Park et al.,
2001; Conlon et al., 2006; Li et al., 2007; Che et al., 2008; Iwakoshi-
Ukena et al., 2011b). However, it was not well determined if “Rana
box” motif, as a widespread disulphide- bridged structure among
anuran AMPs, was an indispensable domain for antimicrobial
activity of these AMPs.
Here, we describe the isolation and identification of a novel
AMP named nigrocin-HL from the skin secretion of H. latouchii
using “shotgun” molecular cloning and mass spectrometry. By
comparing the activity between the synthesized peptide without
“Rana box” and the original peptide against several microbes
in vitro, we dismissed the key role of this motif in maintaining
the antimicrobial potency of nigrocin-HL. Moreover, an analog
of it named nigrocin-HLM was designed and synthesized by
“Rana box”-targeted and C-terminus amidation, which not
only possessed activity against antibiotic-resistant bacteria, but
showed much less toxicity both in vitro and in vivo as well.
MATERIALS AND METHODS
Specimen Biodata and Secretion
Acquisition
Specimens of the oriental broad-folded frog, H. latouchii
(Synonym of Sylvirana latouchii), (sex undetermined; n = 12; 3.5–
5.0 cm in snout-to-vent length) were captured in a mountainous
region of Fujian Province, China. Skin secretions were induced
by mild electrical transdermal stimulation of the dorsal skin,
as described previously (Tyler et al., 1992). After stimulation,
secretions were rinsed with deionized water, and maintained at
4◦C prior to being snap frozen with liquid nitrogen, lyophilized
and stored at−20◦C for further analyses. All the procedures were
subject to ethical approval and carried out under appropriate
U.K. animal research personal and project licenses.
“Shotgun” Cloning of Nigrocin-HL
Precursor-Encoding cDNA
Molecular cloning of nigrocin-HL precursor-encoding cDNA
from a skin secretion-derived cDNA library of H. latouchii were
carried out as described by Gao et al. (2016) with minor changes
as follow: To obtain the full-length peptide precursor nucleic
acid sequence data, the 3’-RACE procedure was performed using
a SMART-RACE kit (Clontech, Palo Alto, CA, United States)
with a NUP primer (supplied with the kit) and a degenerate
sense primer (S1; 5’-GAWYYAYYHRAGCCYAAADATGTTCA-
3’) designed to a highly conserved domain of the 5′ untranslated
region of previously characterized esculentin cDNAs from Rana
species (Chen et al., 2006). Then, purified PCR products
were cloned using a pGEM R©-T easy vector system (Promega
Corporation, United States) and sequenced by an ABI 3100
automated capillary sequencer (Applied Biosystems, Foster City,
CA, United States).
Peptide Modification
To probe the role of “Rana box” structure in nigrocins,
the heptapeptide motif of nigrocin-HL was depleted to
obtain a shorter peptide named nigrocin-HLD (Supplementary
Figure S1). Taken activity improvement and toxicity reduction
into consideration, another peptide nigrocin-HLM was designed
by substituting the “Rana box” with a phenylalanine residue and
C-terminus amidation. The analogs nigrocin-HLD and nigrocin-
HLM and the original peptide were all synthesized by solid-phase
Fmoc chemistry and purified by reverse phase HPLC (RP-HPLC)
for further study.
Determination of Secondary Structures
of Peptides and Validation of Molecular
Models
The I-TASSER and QUARK servers (Zhang, 2008; Xu and Zhang,
2012) were utilized to predict the secondary structures and
deduce the 3D models of nigrocin-HL and its analog nigrocin-
HLM. The 3D models with C-score >−1.5 were selected, which
indicated that these models possessed correct global topology.
Subsequently, the 3D models of the peptides were rendered with
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PyMOL (The EduPyMOL Molecular Graphics System, Version
2.0.2 Schrödinger, LLC). In addition, to correct the disulfide
bridge of nigrocin-HL, the Swiss PDB Viewer (Guex and Peitsch,
1997) was used, as previously described by Porto et al. (2012)
and Porto and Franco (2013). Briefly, the torsions of Gly19
were changed to approximate the Cys residues, then, the bonds
between sulfur and β-carbon atoms were rotated to make the
disulfide bridge. Subsequently, the GROMOS implementation of
Swiss PDB Viewer was used for energy minimization, by 50,000
steps of steepest descent algorithm to remove eventual steric
clashes.
Stereochemical quality of these 3D models were evaluated by
PROCHECK (Morris et al., 1992). And PROSA was applied to
validate model accuracy since it uses knowledge-based potentials
of mean force and shows local model quality by plotting energies
as a function of amino acid sequence position (Maganti et al.,
2010).
Prediction of Physiochemical Properties
A series of physiochemical properties of the peptides, including
hydrophobicity, hydrophobic moments and net charge at neutral
pH, and helical wheels of nigrocin-HL and nigrocin-HLM, were
predicted by Heliquest1.
In addition, hydrophobicity of nigrocin-HL and nigrocin-
HLM was further determined by RP-HPLC. Peptides (1 mg
each) were dissolved in 0.5 ml trifluoroacetic acid (TFA)/water
(0.5/99.95, v/v) (Buffer A) and 0.5 ml TFA/water/acetonitrile
(0.5/19.95/80, v/v) (Buffer B). Supernatant was eluted from an
analytical RP-HPLC Jupiter C5 column (250 nm × 4.6 mm,
Phenomenex, United Kingdom) with a linear gradient from 75%
Buffer A mixed with 25% Buffer B to 100% Buffer B over 36 min
at a flow rate of 1 ml/min, and retention time of each peptide was
recorded.
Additionally, circular dichroism (CD) analyses were carried
out utilizing a JASCO J815 Spectropolarimeter (JASCO Inc.,
United States). Samples were measured within the range of
190–250 nm at 20◦C. The parameters were set as: 200 nm/min
scanning speed, a bandwidth of 1 nm, and 0.5 nm data pitch.
Both peptide samples were dissolved in 10 nM ammonium
acetate buffer and 50% TFE in 10 mM ammonium acetate buffer
at a concentration of 100 µM. The percentage of the α-helix
structure was predicted by the website K2D32 (Louis-Jeune et al.,
2012).
In vitro Antimicrobial Assay
The antimicrobial activity of both natural and designed
peptides was evaluated by MIC and MBC assays utilizing the
broth dilution method. Microorganisms including S. aureus
(NCTC10788), MRSA (NCTC 12493 and ATCC43300),
Escherichia coli (E. coli) (NCTC 10418), Pseudomonas aeruginosa
(P. aeruginosa) (ATCC 27853), Candida albicans (C. albicans)
(NCYC 1467) and four clinical MRSA strains (DTMR8,
DTMR24, DTMR37, and DTMR121) obtained at the First
People’s Hospital of Zhenjiang, China were used. Molecular
1http://heliquest.ipmc.cnrs.fr
2http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d3//
identification of these four clinical isolates was performed by
PCR targeting mecA gene prior to use. After incubation of
peptides (ranging from 1 µM to 512 µM, twofold serial dilution)
and diluted microorganism cultures for 16 h, the absorbance
values of the wells of the 96-well plates were detected at 550 nm
with a Synergy HT plate reader (Biotech, United States) and
the MICs were defined as the lowest concentration of peptides
at which no apparent growth was detected. Ten microliters
of culture in the wells were loaded onto Mueller-Hinton agar
(MHA) medium and incubated at 37◦C for another 18 h. The
MBC of the peptide against a microbe was defined as the lowest
concentration at which no evidence of colony growth was
observed. Five replications were employed for all peptides with
different concentrations and controls, and all measurements
were made in triplicate.
Antibiofilm Assay
Minimum biofilm eradication concentration (MBEC) assay was
carried out with a modified microtiter plate method as described
previously (Gao et al., 2017).
Hemolysis Assay
Hemolytic property of peptides was measured using erythrocytes
prepared from defibrinated horse blood (TCS Biosciences,
Botolph Claydon, Buckingham, United Kingdom) as indicated
previously (Wu et al., 2016).
Cytotoxic Assay
Human keratinocyte cell line HaCaT and human bronchial
epithelial cell line 16HBE were obtained from the ATCC. Cells
were harvested and diluted to 5 × 104 cells/ml using fresh
medium. Ninety-nine microliters of diluted cells and 1 µl of
peptides (final concentration ranging from 1 to 512 µM, twofold
serial dilution, five duplicates) were mixed and seeded into 96-
well culture plates. After incubation for 24 h, 10 µl CCK-8 was
added into each well, followed by incubation at 37◦C for 2 h.
Absorbance of each well was determined, and the viabilities of
cells were calculated as percentages of the control.
In vivo Antimicrobial Assay
BALB/c mice (male, 6–8 weeks old) were purchased from
Qinglongshan Laboratory Animal Company (Nanjing, China),
and maintained under specific-pathogen-free conditions at 18–
25◦C and 50–60% humidity. All procedures involving animals
were approved by the Animal Care and Use Committee of
Nanjing University of Chinese Medicine and performed strictly
according to the Guide for the Care and Use of Laboratory
Animals. Peptides at 10.0 mg/kg and vancomycin at 20 mg/kg
were intraperitoneally injected (i.p.) after mice being nasally
inoculated with MRSA (1 × 107 CFU in 20 µl PBS) for
1 h, subsequently. Twenty-four hours after administration, mice
were euthanized. Mice trachea was cannulated, and 0.5 ml of
cold PBS was infused intratracheally and withdrawn after left
lung was ligated. This procedure was repeated three times, and
consequently, a total volume of 1.2 ml of bronchoalveolar Lavage
Fluid (BALF) was collected. Twenty micrograms of the left lung
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FIGURE 1 | Nucleotide sequence of the cDNA cloned from skin secretion of H. latouchii and its predicted peptide sequence. The putative signal peptide
(underlined), mature peptide (underlined and shaded) and stop codon (asterisk) are indicated.
were homogenized in 0.5 ml of PBS for determining bacterial
burden in the infected lungs. In addition, to measure the degree
of pulmonary edema, the upper lobe of the left lung was excised
and weighed immediately (wet weight). After being dried at 60◦C
for 72 h, weight of the lobe was measured (dry weight), and lung
wet/dry ratio was calculated. The remaining tissue was fixed and
stained with hematoxylin and eosin for pathologic observation,
and the pathologic score for each mouse at a scale of 0–5 was
calculated.
In vivo Toxicities of Peptides
Mice were administered with 20.0 and 40 mg/kg of nigrocin-HL
and nigrocin-HLM (i.p.) and a 7-day mortality was recorded.
Statistical Analyses
Data analyzed are shown as mean ± standard deviations
(SD). Multiple groups were compared with one-way analysis of
variance and two groups with Dunnett’s test, using GraphPad
Prism 7 (GraphPad Software, San Diego, CA, United States). For
MBEC assay, viabilities of nigrocin-HL and nigrocin-HLM at
each certain concentration were compared with two-tailed t-test.
Statistical significance was set at P < 0.05.
Accession Number
GenBank accession number of nigrocin-HL is MH1674083.
3https://www.ncbi.nlm.nih.gov/nuccore/MH167408
RESULTS
“Shotgun” Cloning of Novel Nigrocin-HL
Precursor-Encoding cDNAs From Skin
Secretion-Derived cDNA Libraries of
H. latouchii
A novel nigrocin peptide precursor-encoding cDNAs was cloned
from the skin secretion- derived cDNA library of H. latouchii.
The nucleic acid and translated amino acid sequence of
the novel nigrocin-encoding precursor contained an open-
reading frame (ORF) of 66 amino acid residues (Figure 1).
The translated ORF consisted of a putative signal peptide
(MFTSKKSLLLLFFLGTINLSLC) of 22 amino acid residues, a
mature peptide of 21 amino acid residues, and an acidic spacer
peptide between these two domains. This peptide precursor
showed high similarity to a previously described peptide from the
nigrocin family, named nigrocin-OG20 (Li et al., 2007).
Depletion of “Rana box” Barely Reduced
Antimicrobial Activity of Nigrocin-HL
To assess if the “Rana box” sequence was a key motif to maintain
the bioactivity of the natural nigrocin-HL, we synthesized a
shorter peptide (GLLGGILGAGKKIV) without the heptapeptide
sequence. As suggested by MICs and MBCs listed in Table 1,
the shorter analog showed similar activity against several strains
of bacteria compared with the original peptide. In addition,
both peptides displayed negligible potency against drug-resistant
microbes, including P. aeruginosa (ATCC27853) and six different
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TABLE 1 | MICs and MBCs (mg/l) of nigrocin-HL and its analogs nigrocin-HLD
and nigrocin-HLM against employed microorganisms.
Bacterial strains Nigrocin-HL Nigrocin-HLD Nigrocin-HLM
S. aureus (NCTC10788) 62.70/250.81 42.43/169.73 2.94/5.89
E. coli (NCTC10418) 125.40/ND 84.87/ND 11.77/23.55
C. albicans (NCYC1467) 62.70/501.61 42.43/339.46 2.94/5.89
P. aeruginosa (ATCC27853) ND/ND ND/ND 47.08/47.08
MRSA (NCTC12493) ND/ND ND/ND 5.89/5.89
MRSA (ATCC43300) ND/ND ND/ND 1.47/5.89
DTMR8 ND/ND ND/ND 1.47/2.94
DTMR24 501.61/ND ND/ND 1.47/1.47
DTMR37 ND/ND ND/ND 1.47/2.94
DTMR121 ND/ND ND/ND 1.47/1.47
ND, no detectable activity; all data were quoted in two decimal places.
strains of MRSA. These data indicated that the “Rana box” motif
was not indispensable for nigrocin-HL possessing antimicrobial
activity.
Motif-Targeted Peptide Design
We modified the natural peptide by substituting the heptapeptide
motif with an amidated phenylalanine residue, and an shorter
analog named nigrocin-HLM was obtained (Figure 2A and
Table 2). Our targeted modification, based on the predicted data,
increased the helicity but decreased both the hydrophobicity
and hydrophobic moment of the modified peptide. As shown
in Figure 2B, three dimensional models of these peptides were
predicted by I-TASSER, PyMOL and Swiss-PDB-Viewer and
validated by PROCHECK and PROSA.
In addition, the hydrophobicity of nigrocin-HL and nigrocin-
HLM were determined using RP-HPLC (Figure 2D), and the
retention times suggested that nigrocin-HLM displayed reduced
hydrophobicity compared with the natural peptide. Besides, the
secondary structure of peptides was predicted by CD spectrum
(Figure 2C). In contrast with the natural peptide, the intensity
of band at about 208 nm and 225 nm for nigrocin-HLM in
50% TFE dramatically augmented, which coincided with the
predicted data. As shown in Table 2, the helicity of nigrocin-
HL was 31.28%, and it significantly increased to 50.67% for
nigrocin-HLM after modification.
In vitro and in vivo Antimicrobial
Activities of Nigrocin-HL and Its Modified
Analog Nigrocin-HLM
The MICs and MBCs of nigrocin-HL and nigrocin-HLM
against microorganisms tested are summarized in Table 1.
Nigrocin-HLM was potent against the growth of S. aureus,
E. coli and C. albicans with inhibition being increased
over 10-fold, comparing to the natural peptide. Consistent
with MICs, nigrocin-HLM displayed dramatically enhanced
bactericidal activities against these three representative bacteria
as demonstrated by precipitously declined MBCs. The modified
peptide possessed relatively strong bioactivity against antibiotic
P. aeruginosa (ATCC27853) with MIC and MBC at 32 µM
(47.08 mg/l). Even more intriguing, nigrocin-HLM showed
potent activity against MRSA (NCTC12493, ATCC43300, four
clinical isolates DTMR8, DTMR24, DTMR37, and DTMR121)
with MIC of 4 µM (5.89 mg/l) against NCTC12493 and 1 µM
(1.47 mg/l) against the rest. In sharp contrast with the natural
peptide, nigrocin-HLM also showed bactericidal effect against all
the tested MRSA with MBC not higher than 6 mg/l.
As shown in Figures 3A,B, nigrocin-HLM at 10 mg/kg
significantly ameliorated the lung infection caused by MRSA,
as evidenced by reduced viable bacteria in lung and BALF of
infected mice. Besides, we evaluated the pathological changes
by HE staining (Figures 3D,E) and determining the wet/dry
ratio of lungs (Figure 3C). Results showed that nigrocin-HLM
at 10 mg/kg markedly ameliorated pulmonary inflammation and
edema caused by MRSA, which was even better than vancomycin
at 20 mg/kg. Meanwhile, nigrocin-HL showed similar trend but
relatively weaker potency.
Biofilm Eradication Activity of
Nigrocin-HL and Its Analog Against
MRSA Biofilm
As shown in Figure 4, nigrocin-HLM eradicated MRSA biofilm
with a MBEC concentration of 8 µM (11.77 mg/l), in sharp
contrast with nigrocin-HL which displayed negligible inhibition
of biofilm formation up to 16 µM (31.35 mg/l).
In vitro and in vivo Toxicities of
Nigrocin-HL and Nigrocin-HLM
Despite of potent activities of these two AMPs, toxicities of
them remain to be assessed. Cytotoxicity of nigrocin-HL and
nigrocin-HLM were determined using human keratinocyte cell
line HaCaT and human bronchial epithelial cell line 16 HBE.
Cell growth inhibition of HaCaT and 16HBE occurred with
nigrocin-HL dosages as low as 32 µM, which was not observed
in nigrocin-HLM up to 512 µM (Figures 5A,B). In addition,
hemolytic capacities of these two AMPs were measured against
horse erythrocytes. As shown in Figure 5C, whereas the natural
peptide induced obvious hemolysis at its MICs against tested
microorganisms, the modified nigrocin-HLM showed negligible
hemolytic activity even at the concentrations for it to exert
bactericidal effects. In fact, nigrocin-HLM was found to be devoid
of hemolytic activity up to 128 µM.
Furthermore, acute toxicities of nigrocin-HL and nigrocin-
HLM in vivo were assessed in BALB/c mice via i.p. injection of
different doses of peptides. Survival rates were recorded in 7 days.
After single injection of nigrocin-HL at 20 and 40 mg/kg, mice all
died from day 3 to day 7. In contrast, no mortality was observed
in the two nigrocin-HLM groups within 7 days (Figure 5D).
DISCUSSION
As a hospital-acquired antibiotic-resistant microorganism,
MRSA has causes substantial morbidity and mortality worldwide
(DeLeo et al., 2010). The antibiotic resistance crisis caused by
some developed bacteria, represented by MRSA, has outpaced
the attempts to develop new antibiotics. Under this circumstance,
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FIGURE 2 | (A) Helical wheel plots of peptides were obtained from helical wheel projections, and the direction of summed vectors of hydrophobicity were indicated
as arrows. (B) 3D models of peptides were firstly predicted by I-TASSER. Ramachandran plot of nigrocin-HL generated by PROCHECK showed that 76.9% of
amino acid residues lied in the most favored regions and 23.1% in additional allowed regions. Evaluation of nigrocin-HLM by Ramachandran plot showed that 70%
of residues in the most favored regions and 30% in additional allowed regions. Furthermore, the overall qualities of these 3D models were validated evident based on
the results generated by PROSA. Specifically, the Z scores of nigrocin-HL and nigrocin-HLM were –3.45 and –1.22, respectively. (C) CD spectra of peptides (50 µM)
were recorded in ammonium acetate buffer and in 50% TFE ammonium acetate buffer. (D) Hydrophobicity of nigrocin-HL and nigrocin-HLM were determined using
RP-HPLC.
Frontiers in Microbiology | www.frontiersin.org 6 November 2018 | Volume 9 | Article 2846
fmicb-09-02846 November 28, 2018 Time: 14:25 # 7
Bao et al. Modification Qualifies Nigrocin-HL Greater Potency
TABLE 2 | The predicted physiochemical parameters and percentage of helical structure of nigrocin-HL, nigrocin-HLD, and nigrocin-HLM.
Peptides Sequence Helicity Hydrophobicity Hydrophobic moment Net charge
(%) (H) (µH) (z)
Nigrocin-HL GLLSGILGAGKKIVCGLSGLC 31.28 0.698 0.465 +2
Nigrocin-HLD GLLSGILGAGKKIV 52.32 0.586 0.533 +2
Nigrocin-HLM GLLSGILGAGKKIVF-NH2 50.67 0.667 0.388 +3
AMPs have been considered as promising alternative candidates
against infection especially in the post-antibiotic era (Fjell et al.,
2011). In this present study, we isolated and identified an AMP
named nigrocin-HL from skin secretion of the broad-folded
frog, H. latouchii. This novel AMP bears a heptapeptide motif
(CGLSGLC) named “Rana box,” which is shared throughout
anuran AMPs including brevinins, gaegurins, esculentins,
and nigrocins (Ponti et al., 1999; Kozic et al., 2015). “Rana
box” is mostly constituted by two flanking cysteine residues
separated by other four or five residues, with the second cysteine
being at the C-terminus, it forms a cyclic disulfide bridge
(Iwakoshi-Ukena et al., 2011a). This similarity of AMPs derived
from different species indicates that they are likely to have
an evolutionary origin, the significance of this characteristic
structure on potency of AMPs against microbes remains to
be elucidated, though. Previous paper reported that deletion
of “Rana box” radically abolished the antimicrobial activity of
AMP, while others dismissed its function, as the elimination
or replacement of cysteine residue did not affect potency of
AMPs (Kwon et al., 1998; Vignal et al., 1998; Abraham et al.,
2015).
To confirm whether the “Rana box” sequence is indispensable
for nigrocin-HL to exert its action, we synthesized a shorter
peptide nigrocin-HLD without the motif. In vitro activity assays
suggested that the shorter analog displayed similar efficiency to
the natural peptide against several microbes including Gram-
positive S. aureus, yeast E. coli and Gram- negative C. albicans.
In addition, these two peptides both displayed negligible activity
against drug-resistant P. aeruginosa and several strains of MRSA
except for nigrocin-HL at 256 µM (501.61 mg/l) inhibiting
the growth of a clinical isolated MRSA DTMR24. These data
indicated that the peptide possessed moderate antimicrobial
activity regardless of whether the highly conserved motif “Rana
box” existed or not.
Thus, we modified the natural nigrocin-HL into a shorter
peptide nigrocin-HLM by substituting the motif with a
hydrophobic aromatic phenylalanine residue and amidating the
C-terminus of it. As a result, nigrocin-HLM displayed much
stronger activities against broad spectrum of microorganisms
than nigrocin-HL as evidenced by striking decrease of both
MIC and MBC. Most strikingly, “Rana box” substitution
with phenylalanine residue enabled nigrocin-HLM to exert
potent bacteriostatic as well as bactericidal activity against
seven MRSA strains including five clinical isolates. We further
evaluated antimicrobial activity of peptides in an MRSA-induced
pneumonia mice model, and results indicated that nigrocin-
HLM showed excellent potency against MRSA in vivo, which
was even more efficient than vancomycin at 20 mg/kg. Besides,
since toxicity is one of the major obstacles for AMPs being
applied clinically, both toxicity of peptides in vitro and acute
toxicity in vivo were assessed. Consistent with our expectation
of modification, nigrocin-HLM displayed much less toxicity than
the natural peptide.
To the best of our knowledge, a peptide with potent
antimicrobial efficacy and high selectivity spontaneously should
possess optimum balance between various parameters of it,
including hydrophobicity, secondary structure and cationicity,
etc. (Wimley, 2010). The biological activity of AMPs is strongly
correlated with cationicity of them owing to the fact that AMPs
are initially attracted to the surface of bacterial cell membranes
by the electrostatic force between positively charged residues
within AMPs and anionic phospholipids and lipopolysaccharides
of the bacterial cell membrane. In consequence, AMPs with
more cationic residues should possess stronger antimicrobial
activity theoretically. However, adding cationic residues above
the optimum charge of magainin 2 remarkably decreased its
selectivity for microbial cells and resulted in increased hemolysis
(Dathe et al., 2001). Substitution with a phenylalanine residue
preserved the cationicity of nigrocin-HLM, which helped to
maintain its activity but no more toxicity simultaneously. In
addition, secondary structure and hydrophobicity of peptides
have been considered as other key properties to cooperatively
govern the antimicrobial potency and hemolytic capacity of them.
Earlier, it was reported that moderate hydrophobicity and more
stable helical structure of the 14-helical β-peptide elicited higher
antifungal activity and higher selectivity toward C. albicans (Lee
et al., 2014). It has been widely accepted that a proper balance
between α-helicity and hydrophobicity enhances the potency of
AMPs to penetrate through bacterial membranes, resulting in
membrane disruption and cell death in consequence (Hwang
et al., 2013). In the study described herein, nigrocin-HLM
displayed higher helicity and lower hydrophobicity comparing
with the natural peptide, as demonstrated by CD spectra analysis
and predicted data, respectively. Although the helical-forming
structure “Rana box” was eliminated, the helicity of the modified
peptide significantly increased because of shorter sequence in
general. Besides, two hydrophobic leucine residues were removed
systematically when the “Rana box” sequence was substituted
with one hydrophobic phenylalanine residue, which markedly
reduced the hydrophobicity of nigrocin-HLM as evidenced
by the predicted data and further RP-HPLC confirmation.
Previous paper claimed that higher or lower hydrophobicity
beyond an optimum hydrophobicity window of the 26-residue
peptide V13KL remarkably decreased its antimicrobial activity
(Chen et al., 2007). Nigrocin-HLM, consistent with this theory,
possessed decreased hydrophobicity but showed significantly
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FIGURE 3 | Efficacy of peptides in the MRSA-infected pneumonia mice model. Mice were nasally inoculated with 1 × 107 CFU MRSA. One hour after infection,
normal saline, 20 mg/kg vancomycin and both peptides at 10 mg/kg were administered by i.p. injection. The number of CFU in the lung (A) or in the BALF (B) was
calculated from the number of colonies growing on MHA plates. (C) Effects of nigrocin-HL and nigrocin-HLM on lung inflammation caused by MRSA were analyzed
by lung wet/dry ratio. Left lung of each infected mice was stained with HE and analyzed microscopically. (D) The pathologic score of lungs at a scale of 0–5 was
calculated for each mouse. Data was shown as mean ± SD. Horizontal bars refer to standard deviations. ∗∗∗P < 0.001 versus the model group (normal saline, NS),
and ###P < 0.001 versus the vancomycin (vanco) group. NS, not statistically significant. (E) Lung histopathologic changes of MRSA-induced pneumonia in mice.
The magnification is ×200. The bar length represents 50 µm.
improved and broadened antimicrobial activity in contrast with
the natural AMP, which indicated that our modification helped
to modify the hydrophobicity to an optimum window. And
in accordance with the previous paper, we speculated that
weaker potency of the natural nigrocin-HL might be attributed
to stronger peptide dimerization in solution caused by high
hydrophobicity of it, which prevented access to the membranes
of bacteria (Chen et al., 2007). Meanwhile, the natural peptide
showed much stronger toxicity either in vitro or in vivo, and
there was a substantial chance that its toxicity correlated with
high hydrophobicity-induced self-association because strong
self-association of AMPs enables them to penetrate through
bacterial membranes but interfere eukaryotic cell membranes
as well (Huang et al., 2010). Previously, C-terminal amidation
of PMAP-23 was reported to possess more rapid bactericidal
kinetics and more helical structure of it in the bacterial membrane
environment than the same concentration of PMAP-23C because
of the increased cationic charge (Kim et al., 2011). In addition,
the amidation of C-terminal residue might be responsible for the
stabilization of the secondary helical structure of mastoparans
that is richer than its congener (da Silva et al., 2014). Meanwhile,
Irazazabal et al. (2016) suggested that the increase of net
charge by +1 of [I5, R8] MP-amide might compensate and
overcome the lower level of coil-to-α-helix transition compared
with the non-amidated peptide. Taken these into consideration,
C-terminal amidation of the modified peptide may also facilitate
to its antimicrobial activity by stabilizing membrane interactive
peptide structure and improving the partial charge of the
modified analog. Last but not least, a phenylalanine residue might
also provide extra membrane- binding driving force for nigrocin-
HLM since it contains an aromatic ring (Lee et al., 2013; Datta
et al., 2016).
Prevalently, a cluster of microbes could form biofilms
by attaching to surfaces and producing extracellular
polysaccharides, which enables bacteria grow in a physiologically
distinct way and causes severe infections. MRSA-caused
infection is one of the most worrisome problem for public
health not only because of its multidrug resistance but also
owing to its strong tendentiousness in forming biofilm.
Furthermore, MRSA growing in a biofilm are more recalcitrant
to antibiotics than growing in a planktonic state because of their
low metabolic activity, which enables them resistant to most
antibiotics targeting metabolically active cells (Kanthawong
et al., 2012). The modified peptide nigrocin-HLM at 8 µM
eradicated MRSA-biofilm, in sharp contrast with the natural
nigrocin-HL up to 16 µM showing negligible inhibition of
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biofilm formation. We speculate that nigrocin-HLM inhibits
formation of MRSA-biofilm by permeabilizing and/or forming
pores within the cytoplasmic membrane. Our modification
of the natural nigrocin-HL empowered it with the activity of
FIGURE 4 | Minimum biofilm eradication concentration (MBEC) of peptides
against mature MRSA biofilm. All data represent means ± SD from three
independent experiments performed in triplicate (∗∗∗∗P < 0.0001 versus the
viability of the corresponding concentration of nigrocin-HL).
eradicating MRSA-biofilm, whereas there have not been any
papers reporting antibiofilm potency of nigrocins previously.
To summarize, we firstly dismissed the indispensable role of
the “Rana box” sequence in maintaining the potency of nigrocin-
HL. Subsequently, we optimized the representative parameters of
nigrocin-HLM including hydrophobicity, helicity and cationicity
by substituting the “Rana box” sequence within the natural
peptide with an amidated phenylalanine, which facilitated its
activity against several strains of microbes and notably, our
modification even broadened its potency against antibiotic-
resistant microorganisms including MRSA and P. aeruginosa.
Besides, the analog exhibited high potency to inhibit MRSA not
only in planktonic but biofilm state as well. Most importantly,
the modification significantly attenuated toxicity of nigrocin-
HLM both in vitro and in vivo, raising the possibility of it being
applied clinically. With the encouraging antibacterial activity
and negligible toxicity, nigrocin-HLM should be considered as
a new promising therapeutic candidate against a broad range
of microbes, which may contribute to counter the antibiotic-
resistance threat. Meanwhile, other aspects like administration
route is another prospective where nigrocin-HLM is yet to be
exploited to its utmost.
FIGURE 5 | Toxicities of nigrocin-HL and its analog nigrocin-HLM in vitro and in vivo. Cytotoxicity of nigrocin-HL and nigrocin-HLM against (A) HaCaT and (B)
16HBE. Living cells after treatment with peptides were measured utilizing CCK8 assays, and viability was calculated relative to the untreated control. (C) Hemolysis
of nigrocin-HL and nigrocin-HLM was determined against horse erythrocytes. All data represent mean ± SD from three independent experiments performed in
triplicate (∗P < 0.05, ∗∗∗P < 0.001, compared with nigrocin-HL control group; ###P < 0.001, compared with nigrocin-HLM control group). (D) In vivo toxicities of
these two AMPs. Survival rate of mice in 7 days after single i.p. injection of nigrocin-HL and nigrocin-HLM (20 and 40 mg/kg) was recorded.
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